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Oral Presentations 23Hodgkin lymphoma (NHL). However, long-term outcomes of auto
HCT for HL and NHL have not been well described. We conducted
a retrospective cohort study to evaluate the probability and risk fac-
tors for long-term survival and late relapse in this population. Recip-
ients of auto HCT for HL (N5 407) and NHL (N5 960) between
1990 and 1998 reported to the CIBMTR and in continuous complete
remission (CR) for at least 2 years post-HCT were included in this
study . The median followup was 104 (range, 25–203) months for
HL and 107 (range, 25–198) months for NHL. NHL subtypes
were follicular (30%), diffuse large cell (45%), mantle cell (6%) and
other (7%). The median age of HL patients was 31 years compared
to 47 years for NHL; more HL patients were\20 years (15% vs
5%) while NHL patients were .50 years (6% vs 40%). Patients
were predominantly White (87%), male (60%), with chemosensitive
disease (82%),and KPS score$90 (67%). A greater proportion of HL
patients had history of B symptoms (52% vs 34%) and were $12
months from diagnosis (90% vs 59%) while use of total body irradi-
ation (TBI) was more prevalent for NHL (94% vs 64%). The prob-
ability of overall survival (OS) and cumulative incidence of relapse
and non-relapse mortality (NRM) at 10-years after HCT was 76%
(95% CI, 73–79%), 17% (13–22) and 13% (9–17%) for HL. The
10-year rates of OS, relapse and NRM for NHL were 77%
(72–82%), 26% (23–30%) and 11% (9–13%). On multivariate anal-
ysis, OS (Table) was significantly associated with histology, age at
HCT and time from diagnosis to HCT. Factors predictive for relapse
included histology (compared to HL, relative risk (RR) 1.5 (1.0–2.2)
for follicular, 1.4 (0.9–1.9) for diffuse large cell, 1.4 (0.8–2.8) for lym-
phoblastic/Burkitts, 4.6 (2.8–7.6) for mantle cell and 1.5 (0.9–2.4) for
other NHL), male gender (RR 1.3 (1.0–1.6)), use of TBI (RR 1.6 (1.2–
2.1)), use of growth factors (RR 1.5 (1.1–2.0)) and time since diagnosis
of $12 months (RR 1.9 (1.5–2.6)) while KPS score of $90 at HCT
decreased relapse risk (RR 0.8 (0.6–1.0)). Recipients of auto HCT
for HL and NHL who remain in remission for at least 2 years have
a very favorable subsequent long-term survival. However, they
remain at risk for late relapse and NRM. Mantle cell histology, older
age at HCT and increasing time between diagnosis and HCT are
predictive of adverse long-term survival.
Multivariate analysis for overall survival in patients surviving in
remission for at least 2 years after auto HCT
Variable N RR of death (95%CI) P-valueHistology
HL 399 1.00 \0.01
Follicular NHL 282 0.91 (0.63-1.32) 0.61
Diffuse large cell NHL 422 0.92 (0.64-1.31) 0.63
Lymphoblastic/Burkitts NHL 69 1.28 (0.66-2.48) 0.47
Mantle cell NHL 57 2.87 (1.70-4.87) \0.01
Other NHL 117 0.95 (0.58-1.57) 0.85
Age at HCT
\20 years 101 1.00 \0.01
20-49 years 843 0.94 (0.54-1.66) 0.84
$50 years 402 2.23 (1.24-4.00) \0.01
Time from diagnosis to HCT
\12 months 426 1.00
$12 months 920 2.23 (1.62-3.09) \0.01Other variables considered: gender, race, KPS score, CR status, stage, B
symptoms, chemosensitivity, pre-HCT radiation, pre-HCT chemother-
apy regimens, HCT year, TBI use, graft source, graft purging, growth
factor use and post-HCTradiation.55
GENETIC MODIFICATION OF ANTIGEN-SPECIFIC CYTOTOXIC T LYMPHO-
CYTES (CTLS) RESTORES THEIR ABILITY TO RESPOND TO INTERLEUKIN-
7 (IL-7)
Vera, J.F., Hoyos, V., Savoldo, B., Quintarelli, C., Attianese Greta, G.,
Leen, A.M., Liu, H., Foster, A.E., Heslop, H.E., Rooney, C.M.,
Brenner, M.K., Dotti, G. Baylor College of Medicine, Houston, TX
Adoptive transfer of tumor-specific cytotoxic T lymphocytes
(CTLs) can induces tumor regression in patients with several types
of lymphomas. Clinical responses appear to require the in vivo expan-sion and persistence of the infused CTLs so that IL-2 has frequently
been used to support CTL therapies. Although effective, IL-2 is
associated with significant toxicity and the expansion of regulatory
T cells (Treg). Thus alternative cytokines able to sustain the expan-
sion of CTLs but avoiding the toxic and negative effects of IL-2 are
highly demanded. IL-7 plays a crucial role in T-cell homeostasis, ap-
pears well tolerated, and does not influence Treg numbers or func-
tion. Unfortunately, IL-7 may fail to expand tumor-specific CTLs
in vivo because these cells lack IL-7Ra expression. To determine
whether forced expression of transgenic IL-7Ra improves CTL sur-
vival and expansion we used Epstein-Barr-Virus specific-CTLs
(EBV-CTLs) which we transduced with a retroviral vector encoding
IL-7Ra. After transduction, IL-7Ra was detectable on 58–76% of
EBV-CTLs. The transgenic IL-7Ra molecule was functional since
addition of IL-7 induced STAT5 phosphorylation only in EBV-
CTLs/IL-7Ra1. These EBV-CTLs/IL-7Ra1 and control CTLs
expanded equally in response to IL-2, but only EBV-CTL/IL-
7Ra1 significantly proliferated in the presence of IL-7 (5 ng/mL)
[from 1  106 to 1.03  108 cells/ml (range, 0.38–2.9  108)] over
five weeks of culture. As anticipated, the EBV-CTL/IL-7Ra1 subset
of cells were selected on exposure to IL-7 and so formed an increasing
proportion of the total T cell population. Importantly, IL-7 expanded
EBV-CTLs/IL7Ra1 retained their ability to respond to other com-
mon-g-chain cytokines such as IL-2 and IL-15, and did not modify
their antigen specificity measured by tetramer staining and by
IFNg release. These CTLs also remained polyclonal, retaining
both their effector-memory profile and MHC-restricted killing of au-
tologous LCLs. Antigen or cytokine withdrawal abrogated CTL ex-
pansion. These in vitro characteristics were replicated in a xenograft
mouse model, in which EBV-CTLs/IL7Ra1 expanded in response
to IL-2 or IL-7 and maintained their antitumor effects. In conclusion,
we have developed a novel approach to safely expand adoptively trans-
ferred CTLs using IL-7. This approach can be beneficial for CTL
therapies in patients with lymphomas and other malignancies.PEDIATRIC DISORDERS
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A PILOT STUDY OF REDUCED INTENSITY CONDITIONING (RI) WITH
BUSULFAN (BU), FLUDARABINE (FLU), AND ALEMTUZUMAB FOLLOWED
BY ALLOGENEIC STEM CELL TRANSPLANTATION (ALLOSCT) TO INDUCE
SUSTAINED MIXED DONOR CHIMERISM IN PATIENTS WITH SYMPTOM-
ATIC SICKLE CELL DISEASE (SCD)
Bhatia, M.1, Morris, E.1, Moore, V.1, Tallamy, B.1, George, D.1,
Garvin, J.H.1, Satwani, P.1, Schwartz, J.2, Foley, S.1, Hawks, R.1,
Baxter-Lowe, L.A.3, Cairo, M.S.1,2,4 1Columbia University, New York,
NY; 2Columbia University, New York, NY; 3University of California
San Francisco, San Francisco, CA; 4Columbia University, New York, NY
SCD can be cured by HLA matched family donor AlloSCT (Wal-
ters et al, NEJM, 1996). Patients undergoing myeloablative Al-
loSCT are at risk for many complications post SCT including
death, graft versus host disease (GVHD), and life threatening infec-
tions, thus making RIC regimens an attractive alternative. Having an
unaffected, HLA-matched identical sibling is another major obstacle
for most SCD patients to proceed to AlloSCT(Bhatia et al, BMT,
2008). Umbilical cord blood (UCB) has been proven to be an excel-
lent alternate donor source that can safely reconstitute hematopoie-
sis after AlloSCT(Cairo et al, BBMT, 2008). In this study, we report
the results of RIC and AlloSCT from matched family and UCB do-
nors in 14 patients (12M:2F) with symptomatic SCD (HbSS 5 8,
HbSC 5 3, HbSßThal 5 3). Conditioning was Bu (4mg/kg  4d
# 4 yrs and 12.8mg/ kg  4d . 4 yrs), Flu (30mg/m2  6d), and
Alemtuzumab (2mg/m2  1d, 6mg/m2  2d, and 20mg/m2  2d).
Median age was 6.15 yrs (1.5–16). Donor sources: 6-6/6 HLA-
matched sibling bone marrow (BM), 2-6/6 sibling UCB, 3-4/6
and 3-5/6 unrelated UCB. Bone marrow recipients received median
cell doses of 5.463.5  108 TNC/kg and 4.9861.8  106 CD34/kg
while cord blood recipients received median cell doses of 4.162.0 
107 TNC/kg and 2.261.8  105 CD34/kg. All received tacrolimus
and mycophenolate mofetil as GVHD prophylaxis and phenytoin
or keppra as seizure prophylaxis for 180 days post SCT. Median neu-
trophil and platelet recovery was day 27(0–47) and day 43(0–86), re-
spectively. One patient had primary graft failure at day 160 post
24 Oral PresentationsSCT. Median whole blood donor chimerism on days 30, 60, 100, and
180 was 95%(9–100), 90%(61–99), 90%(60–99), and 91%(88–98),
respectively. Median CD71 chimerism on days 30, 60, 100, and
180 was 98%(17–99), 88%(1–99), 90%(71–99), and 92%(80–96), re-
spectively. Hb electrophoresis demonstrated median %HbS levels of
1.160.1, 060.1, and 1.060.1 on days 30, 60, and 100 respectively.
Of evaluable patients, Grades II-IV acute GVHD was seen in
4/13(30.7%) patients and chronic extensive GVHD was seen in 1/
9 (11.1%) patients. Three patients developed CMV pre-engraftment
(CMV pneumonitis (n 5 2), CMV viremia (n 5 1)) and one devel-
oped CMV viremia post engraftment. OS is 100% (longest follow
up 1491 days). In summary, RIC and AlloSCT in patients with
SCD using both related and unrelated donors has been shown to
be well tolerated and effective in inducing a high degree of
sustained mixed donor chimerism.57
HIGH THROUGHPUT NON-VIRAL GENE TRANSFER OF T CELLS BY
MICRO-ELECTROPORATORS TO GENERATE CD19-SPECIFIC CELLS FOR
IMMEDIATE INFUSION
Choi, Y.1, Maiti, S.1, Yuen, C.1, Huls, H.1, Biswal, S.L.3, Raphael, R.4,
Killian, T.C.5, Stark, D.J.5, Lee, D.A.1, Shpall, E.J.2, Kebriaei, P.2,
Champlin, R.E.2, Cooper, L.J.N.1 1University of Texas M.D. Anderson
Cancer Center, Houston, TX; 2University of Texas M.D. Anderson Can-
cer Center, Houston, TX; 3Rice University, Houston, TX; 4Rice Univer-
sity, Houston, TX; 5Rice University, Houston, TX
Genetic modification of T cells to express a chimeric antigen re-
ceptor (CAR) is a promising therapy for the treatment of malignan-
cies and we have implemented a clinical trial infusing T cells which
express CAR after electro-transfer of DNA plasmid vector. However,
generating CAR1 T cells for diseases that are rapidly progressing,
such as relapsed pediatric B-lineage acute lymphoblastic leukemia
(B-ALL) after allogeneic hematopoietic stem-cell transplantation
(HSCT) is challenging. To meet this challenge we have combined
bioengineering with immunotherapy to develop a new platform tech-
nology for gene transfer of CAR into T cells. This approach side-
steps the problem associated with conventional viral and non-viral
methods for gene transfer that rely on integrating expression vectors
which are typically laborious (sometimes taking weeks of cell-culture
to generate clinically-significant cell doses) and expensive. What is
needed, and is provided here, is a cost-efficient approach to the
genetic transfer of large numbers of minimally manipulated T cells
that can be rapidly modified ex vivo and immediately infused for in
vivo therapy. We have fabricated and tested a series of high through-
put micro-electroporation devices (HitMeds). The initial multi-
electrode HitMed was designed to investigate the electroporation pa-
rameters in a channel with single-cell flow dynamics. Subsequently,
a ‘‘wafer-type’’ HitMed was developed to handle a large number of
T cells in short time. The area of the electrodes of wafer-HitMed is
3,600 mm2 (commercial cuvette: 144 mm2) with a gap, initially set
at 400 mm, but which can be easily changed to enable large numbers
of T cells to be synchronously electroporated. We have adapted the
wafer-HitMed to the electro-transfer of mRNA to avoid genotoxicity
associated with integration. The data in Table 1 demonstrates that
a CD19-specific CAR coded from introduced mRNA is efficiently
electro-transferred into T cells. The expression of CAR transgene
was 80% 24 hours after electroporation as determined by flow cytom-
etry analysis. We recognize that the CAR expression is transient, but
this can be compensated through repeated infusions of the CAR1 T
cells. We foresee the implementation of micro-electroporators to
generate CAR1 T cells for immediate infusion to achieve B-ALL
disease control. As needed, these initial infusions may be followed by
adoptive immunotherapy of T cells with stable CAR expression for
disease eradiation and prevention.Expression of CAR and GFP (%)
Cuvette Cuvette HitMed HitMedCAR GFP CAR GFP
DNA 31.05 44.04 23.95 36.74
mRNA 78.39 82.48 80.02 90.6758
ADENOVIRUS DNA POSITIVITY IN NASOPHARYNGEAL FLUID PRECEED-
ING HAEMATOPOIETIC STEM CELL TRANSPLANTATION: A VERY STRONG
PREDICTOR FOR ADENOVIRUSREACTIVATION IN PEDIATRIC PATIENTS
de Pagter, A.P.J.1, Haveman, L.1, Schuurman, R.2, Bierings, M.B.1,
Boelens, J.J.1 1University Medical Center, Utrecht, Netherlands;
2University Medical Center, Utrecht, Netherlands
Objective: After paediatric haematopoietic stem cell transplanta-
tion (HSCT) adenovirus (HAdV) infection is a severe complication
with high morbidity and mortality rate. By intensive surveillance
patients at high risk for developing HAdV disease can early be iden-
tified in order to start preemptive therapy with antiviral medication
in an early stage.
Methods: In a prospective study, we determined the predictive
value of HAdV DNA positivity in nasopharyngeal fluid preceding
HSCT to identify patients at risk for a plasma HAdV reactivation af-
ter HSCT. We weekly monitored Adenovirus DNA loads in plasma
after HSCT. HAdV reactivation was defined as plasma viral DNA
load .1000cp/mL. Secondly, the association between plasma
HAdV reactivation and alloreactive disease (Graft-versus-Host
disease and/or idiopathic pulmonary syndrome) was analyzed, using
Cox proportional hazard models.
Results: A total of 62 patients were included: 37 (60%) recipients
received bone marrow (17/37, 46%, matched family donor) or
unrelated peripheral blood stem cells while 25 (40%) recipients re-
ceived unrelated cord blood stem cells. 42/62 (68%) recipients re-
ceived HLA-matched stem cells (for BM/PBSC high resolution
typing, for CB intermediate: HLA-A and B on low and HLA-DR
on high resolution). All patients received myeloablative conditioning
and standardized Graft-versus-host disease prophylaxis. The median
follow-up time was 47 (5–150) weeks. Prior to HSCT, HAdV DNA
could be detected in nasopharyngeal fluid of 8/62 patients (13%). In
all these patients (100%), plasma HAdV reactivation occurred
during isolated hospitalization at a median time of 12.5 days (range
5–72 days) after HSCT. Additionally, 11 (18%) patients developed
plasma HAdV reactivation at a median time of 40 (14–160) days after
HSCT. In multivariate analysis HAdV DNA positivity in nasopha-
ryngeal fluid was the only significant predictor for plasma HAdV
reactivation after HSCT (HR 9.7; 95%CI 3.4–27.4; p 5 0.000).
Plasma HAdV reactivation was a predictor for allo-reactive disease
(HR 2.6; 95% CI 1.2–5.4; p 5 0.013).
Conclusions: HAdV positivity in nasopharyngeal fluid pre-
HSCT is a very strong predictor for the development of plasma
HAdV reactivation after HSCT. Prevention or early pre-emptive
treatment with antiviral therapy might contribute to prevent
HAdV disease and / or HSCT associated problems after HSCT.59
UNRELATED CORD BLOOD TRANSPLANTATION (UCBT) OF 30 CONSECU-
TIVE PATIENTS WITH TRANSFUSION-DEPENDENT -THALASSEMIA FROM
A SINGLE CENTER
Jaing, T.-H.1, Wang, B.2, Gjertson, D.4, Petz, L.2, Chow, R.2,3 1Chang
Gung University and Children’s Hospital, Linko, Taiwan; 2StemCyte In-
ternational Cord Blood Center, Covina, CA; 3StemCyte Taiwan National
Cord Blood Center, Linko, Taiwan; 4UCLA School of Public Health, Los
Angeles, CA
UCBT offers a cure for thalassemia and has advantages as a stem
cell source because of the less stringent requirements for an HLA
match between donors and recipients. Previous reports of UCBT
for thalassemia have yielded transplant related mortality (TRM) that
appeared high. It is known that pre-freeze total nucleated cell
(TNC) dose is critical for UCBT. With strategies that maximize
TNC dose – using non-red cell reduced but plasma depleted (PD)
CB, no post-thaw wash (NW), and double cord transplantation
(DCT) when necessary – we have achieved promising results with
UCBT in young patients with transfusion-dependent b-thalassemia.
Between 10/2003 and 5/2008, 39 CB products were infused after
Bu/Cy/ATG myeloablation into 30 pediatric thalassemia major pa-
tients (9 DCT) using NW PD CB exclusively. Patient status: 21 Pe-
saro class-1, 8 class-2, and 2 unknown. Median age was 5 years
(range 1–14 years) with a median weight of 18 kg (range 11–37 kg).
The data was audited by the transplant center (TC) and on-site by
